Back to News
Market Impact: 0.2
Leerink Partners Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt with Outperform Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Leerink Partners initiated coverage of Kazia Therapeutics Limited (NASDAQCM:KZIA) on October 20, 2026, with an Outperform recommendation. The report provides no price target, financial estimates, or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
KZIA0.55
More News
- Why is Contemporary Amperex Technology stock sliding today?
- Capital One's strong quarter and progressing Discover integration are rewarded on Wall Street
- SpaceX Earnings Blow Past Wall Street Estimates
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people